X4 Pharmaceuticals Inc (NASDAQ: XFOR) Stock Forecast: Bullish Signals Pointing To $5 In 2024

In the last trading session, 1.36 million shares of the X4 Pharmaceuticals Inc (NASDAQ:XFOR) were traded, and its beta was 0.46. Most recently the company’s share price was $1.38, and it changed around -$0.03 or -2.13% from the last close, which brings the market valuation of the company to $231.76M. XFOR currently trades at a discount to its 52-week high of $2.58, offering almost -86.96% off that amount. The share price’s 52-week low was $0.57, which indicates that the current value has risen by an impressive 58.7% since then. We note from X4 Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 5.25 million shares, with the 3-month average coming to 2.02 million.

X4 Pharmaceuticals Inc (NASDAQ:XFOR) trade information

Instantly XFOR has showed a red trend with a performance of -2.13% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently up 64.58% year-to-date, but still down -5.48% over the last five days. On the other hand, X4 Pharmaceuticals Inc (NASDAQ:XFOR) is 36.63% up in the 30-day period. We can see from the shorts that 14.22 million shares have been sold at a short interest cover period of 9.06 day(s).

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The consensus price target as assigned by Wall Street analysts is $3.67, which translates to bulls needing to increase their stock price by 62.4% from its current value. Analyst projections state that XFOR is forecast to be at a low of $3 and a high of $5.

X4 Pharmaceuticals Inc (XFOR) estimates and forecasts

X4 Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 26.61 percent over the past six months and at a 8.77% annual growth rate that is well below the industry average of 13.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 6.30% in revenue this quarter, and will report an increase of 97.00% in the next quarter.

5 analysts expect X4 Pharmaceuticals Inc to make $800k in revenue for the quarter ending Jun 2024.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 73.95%.

XFOR Dividends

X4 Pharmaceuticals Inc’s next quarterly earnings report is expected to be released around March 19 and March 25.

X4 Pharmaceuticals Inc (NASDAQ:XFOR)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.83% of X4 Pharmaceuticals Inc shares, and 61.37% of them are in the hands of institutional investors. The stock currently has a share float of 61.89%. X4 Pharmaceuticals Inc stock is held by 118 institutions, with Bain Capital Life Sciences Investors, LLC being the largest institutional investor. By Jun 29, 2023, it held 9.71% of the shares, which is about 15.96 million shares worth $30.96 million.

NEA Management Company, LLC, with 9.11% or 14.99 million shares worth $29.07 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Jun 29, 2023. The former held 5.28 million shares worth $10.25 million, making up 3.21% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 2.79 million shares worth around $3.57 million, which represents about 1.69% of the total shares outstanding.